Your session is about to expire
← Back to Search
Daxdilimab for Lupus Nephritis
Study Summary
This trial will test a new drug to see if it helps with lupus nephritis and is safe to use.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I cannot tolerate low doses of MMF or a similar medication.I was diagnosed with Class V membranous lupus nephritis based on a recent kidney biopsy.You have a condition that weakens your immune system, like HIV infection or having had your spleen removed.I have not been on dialysis in the past year and do not expect to need it soon.You meet the specific medical guidelines for diagnosing systemic lupus erythematosus.You have been diagnosed with a certain type of kidney disease based on a recent kidney biopsy, along with specific levels of protein in your urine and kidney function.I have stopped my immunosuppressants, biologics, and DMARDs as required.I do not have active hepatitis, TB, severe herpes, or any serious infections.I am between 18 and 80 years old.I haven't had major heart problems like a heart attack in the last 6 months.I haven't had cancer in the last 5 years, except for specific skin cancers or cervical cancer that were treated.I do not have kidney diseases that could affect my lupus nephritis assessment.I have not received a live vaccine in the last 4 weeks.Your blood tests show high levels of certain antibodies that indicate an autoimmune disease.I have had allergic reactions to certain medications or treatments before.
- Group 1: Daxdilimab Arm 1
- Group 2: Daxdilimab Arm 2
- Group 3: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the aggregate number of participants in this experiment?
"Affirmative. Information hosted on clinicaltrials.gov supports the fact that this medical study is actively searching for patients, with an initial posting date of November 1st 2022 and a last update date also being November 1st 2022. 210 participants are required from one centre in order to complete the trial."
Who is qualified to take part in this trial?
"Eligible candidates for this trial must be within the 18-80 year old range and possess lupus nephritis. This study is recruiting around 210 patients total."
Does this trial extend to individuals past the age of twenty?
"For this study, only participants over the age of majority and under 80 are eligible to be enrolled."
Are there still openings available for this clinical exploration?
"Affirmative. Clinicaltrials.gov records indicate that this ongoing clinical trial, which was initially published on November 1st 2022, is actively seeking participants. At least 210 individuals are needed from a single medical centre."
What safety parameters have been established for Part 1 of the Daxdilimab protocol?
"The safety of Daxdilimab Arm 1 was rated 2 in our team's estimation, due to Phase 2 clinical trial data indicating a certain level of safety but no established evidence for its efficacy."
Share this study with friends
Copy Link
Messenger